ClinicalTrials.gg
CompletedNCT02268149Updated Oct 20, 2014

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

A Phase 1 interventional study of BIIL 284 BS and Prednisone in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-20.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

Study to evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokinetics of a single dose of prednisone

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written signed and dated prior to participation into the study
  • All participants in the study should be healthy males, aged 18-50 years old inclusive
  • All participants should be within (+- 20%) of their ideal body weight (Broca-Index)
  • Non-smokers (subject who have never smoked) or ex-smoker for at least one year with a smoking history, no greater than five pack-years (1 pack year = 20 cigarettes per day for 1 year)
  • Ability to comply with the concomitant therapy restrictions as detailed in Clinical Trial Protocol (CTP)
  • Subjects will be off all prescription drugs. O.T.C. drugs must be discontinued for at least two weeks prior to participation in the study. If throughout the study, subjects need any O.T.C. medication, the investigator will call the clinical monitor and this will be reviewed on a case-by-case basis. Restrictions for different medications are described in CTP
  • Subjects will have no evidence of concomitant disease based upon complete medical history, full physical examination, chest-x-ray (if not done in previous 6 months), and clinical laboratory tests

Exclusion criteria

Exclusion Criteria:

  • Viral respiratory tract infection or a respiratory tract infection within the six weeks preceding dosing with study medication
  • Small or difficult to locate arm or hand veins that would impair the clinicians ability to draw blood samples or to place a venous catheter
  • Subjects with a known drug or alcohol dependence (absence of dependency for 10 years) or who drink more than 60 g of alcohol per day, history of significant allergic reactions to drugs or sensitivity to aspirin or positive drug screen
  • Use of new drug in the preceding month or six half-lives (whichever is greater) prior to the first screen at Visit 1
  • Donation of blood during the month preceding Visit 1
  • Subjects receiving hyposensitization therapy who are not on a stable dose for the last three months before Visit 1
  • Subjects with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Subjects with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
  • Subjects with known history of orthostatic hypotension, fainting spells or blackouts
  • Subjects with chronic or relevant acute infections
  • Subjects with history of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Subjects with eosinophilia > 7 %
  • Subjects who received any other drugs, which might influence the results of the trial during the weeks prior to dosing with study medication
  • Subjects who participated in excessive physical activities (e.g. competitive sports) within the last week before dosing with study medication
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
20 participants (actual)

Study arms

  • Experimental
    BIIL 284 BS + Prednisone

    BIIL 284 BS 9 days; prednisone 2 single doses

    Drug: BIIL 284 BS · Drug: Prednisone

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. AUC (Area under the concentration-time curve of the analyte in plasma)

    Time frame: up to 72 hours post dose

  2. Cmax (Maximum measured concentration of the analyte in plasma)

    Time frame: up to 72 hours post dose

  3. tmax (Time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 72 hours post dose

  4. t½ (Terminal half-life of the analyte in plasma)

    Time frame: up to 72 hours post dose

  5. MRTtot (total Mean residence time)

    Time frame: up to 72 hours post dose

  6. CLtot/F (Total clearance of the analyte in plasma after oral administration)

    Time frame: up to 72 hours post dose

  7. Vz/F (Apparent volume of distribution of the analyte during the terminal phase)

    Time frame: up to 72 hours post dose

Secondary outcomes

  1. Number of subjects with adverse events

    Time frame: up to 53 days

  2. Changes in immunomodulatory assessed by T-cell proliferation

    Time frame: predose, 4 hours post dose

  3. Changes in Interleukin-2 (IL-2) levels

    Time frame: predose, 4 hours post dose

  4. Changes in Interferon gamma (IFNy) levels

    Time frame: predose, 4 hours post dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2000 and a primary completion of Jul 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2014
First posted
Oct 20, 2014
Start
Apr 2000
Primary completionActual
Jul 2000
Last update
Oct 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02268149
Responsible party
Sponsor
First posted
Oct 20, 2014
Start date
Apr 2000
Primary completion
Jul 2000
Last update
Oct 20, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amelubant · Prednisone

Start the discussion